We conducted a clinical study of MTX-HOPE (day 1, methotrexate 20 mg per os (po); day 2, hydrocortisone 100 mg intravenous (iv), vincristine 1 mg iv; day 3,4 sobuzoxane 400 mg po; etoposide 25 mg po, repeating every 2 or 3 weeks) in 14 relapsed or refractory patients with non-Hodgkin's lymphoma. Ten responders were obtained 5 CR and 5 PR), and heavily treated patients were included in the responders. The median duration of over all survival which was estimated with Kaplan-Meier curve was 11.1 months (range, 2-18+ months), and the median duration of response was 6.9 months (range, 0.8+ -16.4+ months). Out of the 14 patients,eleven were treated with this regimen in an outpatient setting. Grade 4 neutropenia and thrombocytopenia were observed in 4 and 2 patients,and grade 3 GPT-elevation and stomatitis in two and one, respectively. This newly developed MTX-HOPE therapy may be a promising treatment option for such patients as are intolerable for high-dose chemotherapies with PBSC rescue or wish for outpatient therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFEsophageal Candida Infection and Esophageal Cancer Risk in Patients With Achalasia.
JAMA Netw Open
January 2025
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Importance: Patients with achalasia face a higher risk of developing esophageal cancer (EC), but the surveillance strategies for these patients remain controversial due to the long disease duration and the lack of identified risk factors.
Objective: To investigate the prevalence of esophageal Candida infection among patients with achalasia and to assess the association of Candida infection with EC risk within this population.
Design, Setting, And Participants: This retrospective cohort study included patients with achalasia diagnosed at or referred for treatment and monitoring to the Erasmus University Medical Center in Rotterdam, the Netherlands, between January 1, 1980, and May 31, 2024.
Transperitoneal robot-assisted partial nephrectomy: a comparison of operative and oncological outcomes between posterior and anterolateral tumours.
Int Urol Nephrol
January 2025
Department of Urology, Zealand University Hospital, Roskilde, Denmark.
Objective: To compare operative and oncological outcomes, as well as the risk of postoperative complications in patients who underwent transperitoneal robot-assisted partial nephrectomy (RAPN) for renal tumours located either posteriorly or anterolaterally.
Methods: Retrospective, consecutive study including 451 patients who underwent transperitoneal RAPN for non-metastatic, localised renal tumours from May 2016 to April 2023. Operative data included duration of the procedure, warm ischaemia time, and blood loss; oncological data included surgical margins and recurrence; and 90-day postoperative complications were classified according to the Clavien-Dindo classification.
Association between hormone therapy and glioma risk in US women: a cancer screening trial.
Menopause
January 2025
From the Department of Neurosurgery, Chongqing General Hospital, Chongqing University, Chongqing, China.
Objective: Gliomas are the most common primary brain tumors in adults, and the role of hormone therapy (HT) in their development remains controversial. This study with a cohort design aimed to investigate the association between HT use and glioma risk using the data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Methods: We analyzed data from 75,335 women, aged 50-78, who were enrolled between 1993 and 2001.
A Machine Learning Model Using Cardiac CT and MRI Data Predicts Cardiovascular Events in Obstructive Coronary Artery Disease.
Radiology
January 2025
From the Department of Cardiology (T.P., K.H., T.G., A.L., E.G., A.U., J.G.D., P.H.), MIRACL.ai (Multimodality Imaging for Research and Analysis Core Laboratory: and Artificial Intelligence) (T.P., S.T., K.H., T.G., A.L., E.G., A.U., J.G.D., P.H.), Inserm MASCOT-UMRS 942 (T.P., K.H., T.A.S., T.G., A.L., E.G., A.U., J.G.D., P.H.), and Department of Radiology (T.P., V.B., L.H., T.G.), Université Paris Cité, University Hospital of Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; Cardiovascular Magnetic Resonance Laboratory (T.P., T.H., T.U., F.S., S.C., P.G., J.G.) and Cardiac Computed Tomography Laboratory (T.P., T.H., T.L., B.C., T.U., F.S., S.C., H.B., A.N., M.A., P.G., J.G.), Hôpital Privé Jacques Cartier, Institut Cardiovasculaire Paris Sud, Ramsay Santé, 6 Avenue du Noyer Lambert, 91300 Massy, France; Scientific Partnerships, Siemens Healthcare France, Saint-Denis, France (S.T.); Department of Cardiology, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Brussels, Belgium (A.U.); and Department of Cardiovascular Imaging, American Hospital of Paris, Neuilly, France (O.V., M.S.).
Background Multimodality imaging is essential for personalized prognostic stratification in suspected coronary artery disease (CAD). Machine learning (ML) methods can help address this complexity by incorporating a broader spectrum of variables. Purpose To investigate the performance of an ML model that uses both stress cardiac MRI and coronary CT angiography (CCTA) data to predict major adverse cardiovascular events (MACE) in patients with newly diagnosed CAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!